

Order: 180821-0060

Client #: 24510 aboratory Street KS 66214 USA

Ph.D. Director

Sex: Female

LMP: 07/21/2018

Patient: Kaveri Alaghappan

Age: 33 DOB: 12/27/1984

Body Mass Index (BMI): 18.6

Menopausal Status: Pre-menopausal,

Id: P181000105 Client Ref: 605257

Date Collected Morning Noon

Date/Time 08/12/2018 08/12/2018 0745

Evening Niaht

08/12/2018 1345 08/12/2018 1800

Date Received Date Reported

Sample Collection

08/12/2018 2200 08/21/2018 08/23/2018

| Analyte Result | | Unit | b e L | | H Reference | H Reference Interval | | Supplementation Range** | | |
|---------------------------|------|-------|-------|---|-------------|----------------------|------------|-------------------------|--|--|
| Estrone (E1)* | 16.9 | pg/mL | | • | <45 | Horn | | | | |
| Estradiol (E2) | 0.70 | pg/mL | | | 0.5 - 5.0 | | 1.5 - 7.2 | | | |
| Estriol (E3)* | <5.0 | pg/mL | | • | < 66 | | 67 - 708 | | | |
| EQ (E3 / (E1 + E2)) Ratio | 0.28 | | + | | >1.0 | | | | | |
| Progesterone (Pg) | 96 | pg/mL | + | | 127 - 446 | | 500 - 3000 | | | |
| Pg/E2 Ratio | 137 | | + | | 200 - 600 | | | | | |
| Testosterone | 7 | pg/mL | | • | 6.0 - 49 | | 30 - 60 | | | |
| DHEA* | 44 | pg/mL | 1 | | 106 - 300 | | | | | |



Hormone Comments:

- Estrone, estradiol and estriol are within the reference ranges, however the Estrogen Quotient (EQ) is low. Estriol is less potent than the other estrogens and when present in sufficient quantities (as indicated by an optimal EQ) it plays an antagonistic role, and may govern the proliferative effects of estrone and estradiol. Estriol supplementation is a consideration to balance this quotient and reduce associated risks. .
- Progesterone to estradiol (Pg/E2) ratio and reported symptoms are consistent with progesterone insufficiency (estrogen dominance). Supplementation with topical progesterone to correct this relative deficiency is a consideration. Note: The progesterone level is suggestive of an anovulatory cycle, luteal phase failure or collection outside of luteal phase. .
- DHEA levels typically decline with age and the level measured here is below the reference range. The low DHEA level may warrant supplementation for optimal well-being. Note: Supplementation with DHEA may increase testosterone and/or estradiol levels.

Notes:

Estriol result confirmed via repeat analysis

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

The Pg/E2 ratio is an optimal range established based on clinical observation. Progesterone supplementation is generally required to achieve this level in men and





Adrenal Hormone Report; saliva

Laboratory, Inc

Ph.D., Director

KS 66214

Fax (913

Order: 180821-0060

Client #: 24510

Laboratory h Street 66214 USA Patient: Kaveri Alaghappan Id: P181000105 Client Ref: 605257

Age: 33 **DOB:** 12/27/1984 **Sex:** Female

Body Mass Index (BMI): 18.6

Menopausal Status: Pre-menopausal, LMP: 07/21/2018

Date Collected Morning Noon Evening Night

Sample Collection

08/12/2018 08/12/2018 0745 08/12/2018 1345 08/12/2018 1800


Date/Time

 Night
 08/12/2018 2200

 Date Received
 08/21/2018

 Date Reported
 08/23/2018

| Analyte | Result | Unit | (Company) | WR | Н | Optimal Range | Reference Interval | |
|------------------|--------|--------|-----------|----|---|---------------|--------------------|--------|
| Cortisol Morning | 7.3 | nmol/L | dia | | | 18-35 | 5.1-40 | united |
| Cortisol Noon | 2.8 | nmol/L | | | | 6.0 - 12 | 2.1 - 16 | |
| Cortisol Evening | 0.58 | nmol/L | 4 | | | 2.0 - 5.0 | 1.5 - 8.0 | |
| Cortisol Night | 0.99 | nmol/L | | | | 1.0 - 4.0 | 0,33 - 7.0 | |
| DHEA* | 44 | pg/mL | B19: 12. | | | | 106 - 300 | |



Hormone Comments:

- Diurnal cortisol pattern and reported symptoms are consistent with evolving (Phase 2) HPA axis (adrenal gland) dysfunction.
- DHEA levels typically decline with age and the level measured here is below the reference range. The low DHEA level may warrant supplementation for optimal well-being. Note: Supplementation with DHEA may increase testosterone and/or estradiol levels.

Notes:

5/15/2019 8:59:45 PM PAGE

2/002

Fax Server

WA 98032

Received: 5/10/2019

Completed: 5/15/2019

(

Accession: 19-21123

Phone: 215-

Fax: 1-215-

Reported: 5/15/2019

Results For: ALAGHAPPAN, KAVERI

Age: 34 DOB: 12/27/1984 Sex: F

Patient's Tel: 1-484-302-0262

Ref. ID:

Specimen Collected: 5/4/2019

QUAKERTOWN, PA 18951

ePeriM

Expanded Perimenopause Hormone Panel - Saliva

| Free Fraction - Hormone | Res | sults | Romas |
|---|------------|------------|--|
| Free Fraction - Hormone | 1st Sample | 2nd Sample | Range |
| DHEA - Dehydroepiandrosterone [DHEA + DHEA-S] (saliva) | 1 Low | 1 Low | Adults: 3-10 ng/ml |
| TTF - Testosterone (saliva) | 49 High | 36 Normal | Adults Borderline: 6-9 pg/ml Normal: 10-38 pg/ml |
| E1 - Estrone (saliva) | 151 High | 16 Low | Normal for Age 16-39: 30-58 pg/ml |
| E2 - Estradiol (saliva) | 12 | 4 | Postmenopause-No HRT: 1-4 pg/ml BHRT Target Range: 2-10 pg/ml Follicular: 2-10 pg/ml Luteal: 3-16 pg/ml |
| E3 - Estriol (saliva) | 50 High | 14 | Postmenopause-No HRT: 7-18 pg/ml BHRT Target Range: 14-38 pg/ml Cycling Female: 12-25 pg/ml |
| P1 - Progesterone (saliva) | 33 | 69 | Postmenopause-No HRT: 5-95 pg/ml BHRT Target Range: 100-300 pg/ml Follicular: 20-100 pg/ml Luteal: 65-500 pg/ml |
| FSH - Follicle stimulating hormone (saliva) | 41 | 67 | Cycling Female: <125 uIU/mL Postmenopause: 90-500 uIU/mL |
| LH - Luteinizing hormone (saliva) | 42 | 28 | Cycling Female: 8-30 uIU/mL HRT: 8-30 uIU/mL Postmenopause-No HRT: 25-200 uIU/mL |

Note: The BHRT target range is based on optimal physiological hormone levels in cycling females. Current or previous topical hormone use or inadvertent exposure may lead to increased salivary hormone levels that exceed physiological or BHRT target ranges.

Diagnosis Code(s): Not Provided To The Lab

Results and comments above are intended for informational purposes and should not be construed as medical advice. Use this report in context of the clinical picture and patient history before initiating any treatment.

COURTESY INTERPRETATION of test and technical support are available upon request, to Physicians Only.

SCANNED

Patient Report

Patient: ALAGHAPPAN, KAVERI DOB: 12/27/1984 Pa **Specimen ID:** 046-504-0551-0 **Patient ID:** Control ID: 10462458881 Date collected: 02/15/2019 0943 Local

| TE | STS R | ESULT | FLAG | UNITS RE | FERENCE INTERVAL | LAB |
|--|--|--|---|--|---|----------|
| | - | - 30 da - 5 mor 6 mor - 11 mor 1 yea - 3 yea - 6 yea - 9 yea 10 yea 11 yea 12 yea 13 yea - 15 yea 16 yea - 100 yea | nths nths nths ars ars ars ars ars ars | Not estab. 1 - 30 2 - 52 2 - 82 3 - 200 6 - 366 14 - 710 19 - 893 22 - 1055 22 - 1055 16 - 810 19 - 893 20 - 798 18 - 628 6 - 495 | Not estab. 0 - 16 1 - 24 2 - 82 2 - 100 4 - 227 6 - 455 12 - 708 12 - 708 12 - 796 12 - 796 12 - 796 9 - 681 6 - 681 9 - 472 6 - 495 | |
| Pregnenolone, Reference Adults: | e Range: | 36 | | ng/dL | | 03 |
| Hemoglobin Ald Hemoglobin Ald Please Note: | | | s with | % diabetes: <7. | 4.8 - 5.6 | 02 02 |
| DHEA-Sulfate | | 33.3 | Low | ug/dL | 84.8 - 378.0 | 02 |
| Testosterone, | Serum | 4 | Low | ng/dL | 8 - 48 | 02 |
| Prolactin | | 10.9 | | ng/mL | 4.8 - 23.3 | 02 |
| Estradiol Roche ECI | LIA methodology | 205.3 | Ovula Lutea Postm Pregnar 1st t | cular phase ation phase al phase menopausal ncy | 12.5 - 166.0 85.8 - 498.0 43.8 - 211.0 <6.0 - 54.7 215.0 - >4300.0 6.0 - 27.0 | 02 |
| Medicine level of The Endo insuffic | -Hydroxy D deficiency has beand an Endocrine serum 25-OH vitamerine Society went iency as a level beattute of Medic | Society pin D less on to fuetween 21 ine). 201 | oractice s than 2 urther of l and 29 | e guideline as 20 ng/mL (1,2) define vitamin 9 ng/mL (2). | a · D | 02 |

Alaghappan, Kaveri

Patient ID:

Specimen ID: 232-504-9595-0

DOB: 12/27/1984

Age: 36

Sex: Female

Patient Report

Account Number: 37092603

Ordering Physician:

Iron and TIBC

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|----------------------|-------------------------|--------------------------|-------|--------------------|
| Iron Bind.Cap.(TIBC) | 368 | | ug/dL | 250-450 |
| UIBC 01 | 307 | | ug/dL | 131-425 |
| Iron ^{a1} | 61 | | ug/dL | 27-159 |
| Iron Saturation | 17 | | % | 15-55 |

DHEA, Serum

| Test | Current Result and Flag Previous Result and Date | | Units | Reference Intervi |
|-------------------------------|--|---------------|----------|-------------------|
| Dehydroepiandrosterone (DHEA) | | | | |
| V 03 | 54 | | ng/dL | 31-701 |
| \sim | | | | |
| | | | | |
| | | Age | | |
| | | 1 - 5 years | 0 - 67 | |
| | | 6 - 7 years | 0 - 110 | |
| | | 8 - 10 years | 0 - 185 | |
| | | 11 - 12 years | 0 - 201 | |
| | | 13 - 14 years | 0 - 318 | |
| | | 15 - 16 years | 39 - 481 | |
| | | 17 - 19 years | | |
| | | >19 years | | |
| | | 17 your | 2. 701 | |

Vitamin D, 25-Hydroxy

| Test | Current Result and Flag | Previous Result and Date | | Units | Reference Interval | | |
|--|--|--------------------------|---|-----------------------|--------------------|--|--|
| Vitamin D, 25-Hydroxy 11 | 36.1 | 26.1 01/24/2020 | | ng/mL | 30.0-100.0 | | |
| | | | *************************************** | ********************* | | | |
| | Vitamin D deficiency has bee | n defined by th | e Institute of | | | | |
| | Medicine and an Endocrine So | ciety practice | guideline as a | | | | |
| | level of serum 25-0H vitamin | D less than 20 | ng/mL (1,2). | | | | |
| | The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | intakes for calcium and D | • | • | | | | |
| | National Academies Press. | | | | | | |
| | 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. | | | | | | |
| Evaluation, treatment, and prevention of vitamin D | | | | | | | |
| | deficiency: an Endocrine Society clinical practice | | | | | | |
| | guideline. JCEM. 2011 Jul | .: 96(7):1911-30 | • | | | | |
| | • | | | | | | |

Homocyst(e)ine

| Test | Current Result and Flag | Previous Res | ult and Date | Units | Reference interval | |
|-------------------|-------------------------|--------------|--------------|--------|--------------------|--|
| Homocyst(e)ine 01 | 9.8 | 11.9 | 01/24/2020 | umol/L | 0.0-14.5 | |

labcorp